Nebularine

Nebularine

SCHEMBL742475

OC[C@@H]1O[C@@H](n2cnc3cncnc32)[C@H](O)[C@H]1O

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 1/20 0.65
KDM4E B2RXH2 1/20 0.62
PKM P14618 1/20 0.62
DPP4 P27487 1/20 0.60
MEN1 O00255 1/20 0.60
SLC28A1 O00337 1/20 0.60
MAP3K7 O43318 1/20 0.60
SLC28A2 O43868 1/20 0.60
GAPDH P04406 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
MAPK1 P28482 1/20 0.60
ADORA2A P29274 1/20 0.60
ADORA2B P29275 1/20 0.60
ADORA1 P30542 1/20 0.60
STAT6 P42226 1/20 0.60
PI4KA P42356 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PI4K2B Q8TCG2 1/20 0.60
DOT1L Q8TEK3 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nebularine SCHEMBL9644429 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL29799158 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL93409 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL1894168 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL745560 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL10666450 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL27552329 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL29362246 1.00 ADA (0.65) ADAKDM4EPKMDPP4MEN1
SCHEMBL25170484 0.99 ADA (0.64) ADAKDM4EPKMDPP4MEN1
Nebularine SCHEMBL8895399 0.99 ADA (0.64) ADAKDM4EPKMDPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318556-A1 BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2009-12-24 US claimed
CN-1612739-A Method for treating or preventing inflammatory diseases INSPIRE PHARMACEUTICALS INC (US) 2005-05-04 CN claimed
EP-0986396-A4 PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS UNIV CALIFORNIA (US) 2003-05-02 EP claimed
US-6500652-B2 OLIGONUCLEOTIDE OF >/=4 NUCLEOTIDES THAT HAS A VIRAL NUCLEIC ACID SEQUENCE WHICH INCLUDES THE INITIATION NUCLEOTIDE ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. 2002-12-31 US claimed
US-20020103143-A1 USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. 2002-08-01 US claimed
US-6355472-B2 ACID PHOSPHATASE AJINOMOTO CO., INC. (JP) 2002-03-12 US claimed
US-20020004590-A1 Method for producing nucleoside-5'-phosphate ester MIHARA YASUHIRO (JP) 2002-01-10 US claimed
US-6207435-B1 MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES AJINOMOTO CO., INC. (JP) 2001-03-27 US claimed
EP-1052265-A1 PROCESS FOR PRODUCING NUCLEOSIDE DERIVATIVES Ajinomoto Co., Inc. (JP) 2000-11-15 EP claimed
EP-0986396-A1 PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS The Regents of the University of California (US) 2000-03-22 EP claimed
US-6015697-A ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY AJINOMOTO CO., INC. (JP) 2000-01-18 US claimed
WO-1999049031-A1 USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) 1999-09-30 WO claimed
WO-1998055132-A1 PRION PROTEIN MODULATOR FACTOR (PPMF) AND PRION RESISTANT ANIMALS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-12-10 WO claimed
EP-4403042-A2 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME Mars, Incorporated (US) 2024-07-24 EP disclosed
EP-3229612-B1 USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS INC (US) 2024-06-26 EP disclosed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
WO-1992012718-A1 ADENOSINE KINASE INHIBITORS GENSIA, INC. (US) 1992-08-06 WO disclosed
US-4016262-A ANTILIPOLYTIC, HYPERLIPEMIA, ANTICHOLESTEROL AGENTS BOEHRINGER MANNHEIM G.M.B.H. (DT) 1977-04-05 US disclosed
US-3988317-A ANTICHOLESTEROL AGENTS BOEHRINGER MANNHEIM G.M.B.H. (DT) 1976-10-26 US disclosed
US-3932656-A SYNTHETIC POLYMER, PROSTAGLANDIN ALZA CORPORATION (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318556-A1 BIOMARKERS FOR DETECTING RADIATION EXPOSURE: METHODS AND USES THEREOF OGG1, UNG, HPRT1 ADA 777/4885KDM4E 4016/4885PKM 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.